Cannabis Report across cannabis plants
(Source: File image)

Canopy Growth has added new softgel capsules under its Spectrum Therapeutics medical cannabis brand in Australia in response to rising demand for product diversity. The softgels join Spectrum Therapeutics’ growing product suite, including oils and flower, in addition to flower under other Canopy Growth brands.

Cannabis softgels. (Source: Adobe Stock. Generated by AI)

Click here for the full story.

Weekly Update – Top Cannabis News Stories

1 |  Planet 13 launches exclusive partnership to Bring ONI’s products to Florida

2 | Canopy Growth expands Spectrum Therapeutics portfolio in Australia with new softgels

3 |  Biorem reports record order backlog, $11.3 million of revenues in the quarter

4 | Decibel reports 37 per cent year over year net revenue increase of $32.9 million


Top Cannabis Stocks Nov. 14 to Nov. 19, 2025

1. T.TLRY | 4,1334views | Tilray Brands Inc.
2. T.LABS | 3,698 views | Medipharm Labs Corp.
3. T.CURA | 3,543 views | Curaleaf Holdings Inc.
4. T.WEED | 1,454 views | Canopy Growth Corp.
5. C.TGIF | 483 views | 1933 Industries Inc.
6. T.OGI | 432 views | Organigram Global Inc.


Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.



More From The Market Online

@ the Bell: TSX lifted by strong earnings from Big Six banks

The TSX Index added more than 1 per cent on Thursday driven by strong earnings from Canada’s Big Six banks.

Market Open: Salesforce Gains, EQB Buys PC Financial, Copper Slips | Dec 04, 2025

TSX rises 0.36% as Salesforce jumps 2% and EQB acquires PC Financial. Dow dips, gold edges higher, copper and Bitcoin fall.

Buzz on the Bullboards: Cannabis stock split, major financing, and battery breakthrough

Inflation concerns, lofty valuations, and growing uncertainty around returns from have prompted investors to reassess their AI exposure.